Vitiligo Study

Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Adult and Adolescent Participants with Non-Segmental Vitiligo

Study Purpose

The purpose of the study is to evaluate whether the study drug, Ritlecitinib, is effective in managing vitiligo and if it is safe for human use. The study drug will be compared with a placebo, a study drug that does not contain any active ingredients, to find out if the study drug is better than the placebo for the study treatment of vitiligo.

Who Can Participate

Participants 18 years and older diagnosed with non-segmental vitiligo may be eligible for this study.